-

Shareholder Alert: Robbins LLP is Investigating Clover Health Investments, Corp. (CLOV) on Behalf of Shareholders

SAN DIEGO & FRANKLIN, Tenn.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Clover Health Investments, Corp. (NASDAQ: CLOV) on behalf of shareholders to determine whether certain Clover officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Clover Health provides medical insurance services.

If you suffered a loss due to Clover Health Investment Corp.'s misconduct, click here.

Clover Health Investment, Corp. (CLOV) Misled Shareholders Ahead of Going Public

According to a class action complaint filed against Clover Health, on October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company via a merger with Social Capital Hedosophia Holdings Corp. III ("SCH"). SCH was a special purpose acquisition company (SPAC) that traded on the NYSE under IPOC.

On January 7, 2021, Clover and SCH announced it had completed the business combination and that shares of Clover would trade on NASDAQ under ticker symbol CLOV the next day. On February 4, 2021, Hindenberg Research published a report revealing "how Clover Health and its Wall Street celebrity promoter, Chamath Palihapitiya, misled investors about critical aspects of Clover's business in the run-up to the company's SPAC go-public transaction last month." Notably, Hindenberg revealed that Clover's business model and software offering "are under active investigation by the Department of Justice (DOJ), which is investigating at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals." On this news, shares of Clover dropped more than 12% from $13.95 on February 3, 2021, to $12.23 on February 4, 2021, representing a loss of $700 million in market capitalization. The stock continued to tumble and now trades at just $8.40.

Clover Health Investment, Corp. (CLOV) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Clover Health Investment, Corp. settles or to receive free alerts about company executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom